Who
Ying Luo
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Gyre Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $166K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Oct 2023
- Last trade
- 8 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 10 Jun 2026 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $81K10,136 at $8.04 | filing |
| 6 May 2026filed 7 May 2026 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $81K10,136 at $8.04 | filing |
| 5 May 2026filed 7 May 2026 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,434179 at $8.01 | filing |
| 5 May 2026filed 7 May 2026 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,434179 at $8.01 | filing |
| 14 Aug 2024filed 16 Aug 2024 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 20 Nov 2023filed 22 Nov 2023 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,350,897 at $0.00 | filing |
| 20 Nov 2023filed 22 Nov 2023 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,262,755 at $0.00 | filing |
| 31 Oct 2023filed 1 Nov 2023 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,866 at $0.00 | filing |
| 30 Oct 2023filed 22 Nov 2023 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code J | —2,840,376 | filing |
News
Gyre Therapeutics (NASDAQ:GYRE) vs. GSK (NYSE:GSK) Head-To-Head ContrastGYRE · dailypolitical.com · 19 Oct 2026GSK (NYSE:GSK) versus Gyre Therapeutics (NASDAQ:GYRE) Financial ContrastGYRE · themarketsdaily.com · 15 Oct 2026Contrasting Scienture (NASDAQ:SCNX) & Gyre Therapeutics (NASDAQ:GYRE)GYRE · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Ying Luo; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.